Funding And Financial SupportOPKO purchased roughly 3.7 million ordinary shares of Entera for $8 million, providing funding for Entera's share of the development costs.
Partnerships And CollaborationsEntera Bio and OPKO Health have entered into a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic disorders.
Regulatory ApprovalThe FDA agreed to Entera Bio's proposal that the New Drug Application for its lead candidate EB613 would be supported by a single multinational, randomized, double-blind, placebo-controlled, 24-month Phase 3 study in women with post-menopausal osteoporosis.